drugset

drugset / Trial / NCT00499863

Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

NCT00499863 ↗

Phase 3 Completed 217 enrolled Noven Therapeutics

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To assess the efficacy and safety of efficacy of MTS compared to placebo

Timeline

Start: 2007-07
Primary completion: 2008-05
Completion: 2008-05

Publications

Results Findling RL, Turnbow J, Burnside J, Melmed R, Civil R, Li Y. A randomized, double-blind, multicenter, parallel-group, placebo-controlled, dose-optimization study of the methylphenidate transdermal system for the treatment of ADHD in adolescents. CNS Spectr. 2010 Jul;15(7):419-30. doi: 10.1017/s1092852900000353.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Methylphenidate	Small molecule	10 mg	Other
Subject	Methylphenidate	Small molecule	15 mg	Other
Subject	Methylphenidate	Small molecule	20 mg	Other
Subject	Methylphenidate	Small molecule	30 mg	Other

Indications